-
New Two-Year Data on CRENESSITY® (crinecerfont) Shows Lasting Health Benefits for Children with Classic Congenital Adrenal Hyperplasia
NASDAQ: $NBIX Recent findings presented at the Pediatric Endocrine Society 2026 Annual Meeting offer a promising outlook for the pediatric community living with classic congenital adrenal hyperplasia (CAH). Neurocrine Biosciences has released new two-year data from the Phase 3 CAHtalyst® Pediatric study, revealing that long-term treatment with CRENESSITY® (crinecerfont) provides durable hormone control and allows…
-
Viatris Advances Contraceptive Care: New Data on Weekly Low-Dose Patch to be Presented at ACOG 2026
NASDAQ: $VTRS As we approach the 2026 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting in Washington, D.C., the medical community is turning its attention toward significant advancements in reproductive health. Viatris Inc. recently announced it will present six new abstracts regarding its investigational low-dose estrogen combined hormonal contraceptive (CHC) weekly…
-
Kodiak Sciences Advances Pipeline and Unveils New Clinical Data for KSI-101 in Uveitis Treatment
NASDAQ: $KOD Kodiak Sciences Inc. has announced significant progress in its clinical and scientific programs, with plans to present new data at the 2026 American Uveitis Society (AUS) Meeting and the Association for Research in Vision and Ophthalmology (ARVO) Meeting. These updates center on the clinical performance of KSI-101 in treating macular edema secondary to…
-
Expanding Global Protection: Genprex Secures Key Patent for Reqorsa® Gene Therapy in Israel
NASDAQ: $GNPX In a significant move to strengthen its international intellectual property portfolio, clinical-stage gene therapy company Genprex, Inc. (NASDAQ: GNPX) recently announced that the Israel Patent Office (ILPO) has officially granted a patent covering the use of its proprietary Reqorsa® gene therapy (quaratusugene ozeplasmid) in combination with PD-1 antibodies for cancer treatment. Strategic Intellectual…
-
Insmed Sets Sights on May 2026: What Investors Should Watch
NASDAQ: $INSM Insmed Incorporated has officially announced its participation in a series of upcoming investor conferences throughout May 2026. This move signals a proactive effort by the biopharmaceutical company to maintain transparency and provide clarity regarding its ongoing clinical pipeline and commercial strategies. Why These Appearances Matter Investor conferences serve as a critical bridge between…
-
Advancing Crohn’s Disease Treatment: The Potential of RedHill’s RHB-204
NASDAQ: $RDHL The landscape of Crohn’s disease (CD) treatment may be on the cusp of a significant shift. RedHill Biopharma Ltd. recently announced promising in vitro testing results for RHB-204, a next-generation oral formulation that represents a targeted therapeutic approach to the condition. By focusing on Mycobacterium avium subspecies paratuberculosis (MAP), RedHill is pursuing a strategy…
-
Advancing Large-Bore Venous Access: New Study Validates VASCADE MVP® XL Performance
NYSE: $HAE In the rapidly evolving field of cardiac electrophysiology, the precision of venous access closure is as critical as the primary procedure itself. Haemonetics Corporation recently announced compelling new clinical evidence regarding its VASCADE MVP® XL venous vascular closure system, marking a significant milestone for procedural safety and efficiency in large-bore venous access. The…
-
New Two-Year Data Supports Long-Term Management of Classic Congenital Adrenal Hyperplasia with CRENESSITY®
NASDAQ: $NBIX For individuals living with classic congenital adrenal hyperplasia (CAH), the standard of care has long presented a difficult dilemma. While patients require glucocorticoids (GCs) to survive, the historical reliance on supraphysiologic doses—doses higher than what the body naturally produces—has carried a heavy burden of long-term health risks, including metabolic complications, bone density loss,…
-
Advancing Oncology: Mount Sinai Health System Partners with SOPHiA GENETICS to Elevate Precision Cancer Care
NASDAQ: $SOPH In a significant move for the future of precision medicine, the Mount Sinai Health System has announced a strategic collaboration with SOPHiA GENETICS. This partnership marks a new chapter for one of the nation’s most prestigious academic health systems, as it integrates the AI-powered SOPHiA DDM™ Platform to refine its genomic testing capabilities…
-
Hoth Therapeutics Leverages OpenClaw™ AI Platform to Advance Drug Discovery
NASDAQ: $HOTH Hoth Therapeutics Deploys OpenClaw™ AI Platform to Accelerate Drug Discovery Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, has announced a significant strategic advancement with the deployment of OpenClaw™, its new, advanced AI-enabled computational platform. This move signifies a major commitment to integrating artificial intelligence into the core of its drug discovery and development…
-
Alliance for Genomic Discovery Scales Up: Regeneron Joins, Multiomic Data Initiative Launched
NASDAQ: $ILMN Genomic Research Reaches New Heights with Expansion and Proteomic Integration The landscape of genomic discovery is undergoing a significant transformation with major developments announced by the Alliance for Genomic Discovery (AGD), a collaboration spearheaded by Illumina, Inc. and Nashville Biosciences, LLC (NashBio). Two key announcements signal a massive leap forward: the addition of…
-
Promising Early Results: LYMPHIR™ Shows Potential to Enhance CAR-T Therapy in High-Risk DLBCL
NASDAQ: $CTOR Citius Oncology, Inc., a key player in oncology biopharmaceuticals and a subsidiary of Citius Pharmaceuticals, Inc., recently shared encouraging topline safety and efficacy results from an investigator-initiated Phase 1 trial. This study explored the utility of LYMPHIR™ (E7777, denileukin diftitox?cxdl) when administered as a preparatory treatment before commercial CD19-directed CAR-T cell therapy for…
-
Hoth Therapeutics Leverages OpenAI API to Accelerate Development of Orphan Oncology Program, HT-KIT
NASDAQ: $HOTH Hoth Therapeutics, Inc., a biopharmaceutical company dedicated to patient-focused therapies, recently announced a significant strategic move: the deployment of the OpenAI API to bolster the development of its orphan-designated therapy, HT-KIT. This innovative integration targets rare and aggressive KIT-driven cancers, marking a forward-thinking approach to drug development within the oncology space. AI Integration…
-
FREE BIO-TECH STOCK CATALYST REPORT FOR WEEK OF 03-01-2026 TO 03-07-2026
We’re excited to announce the release of our latest free bio tech stock catalyst report for the upcoming week. This new free stock report highlights bio tech companies that have an upcoming important event to help traders and investors make informed decisions in today’s dynamic environment. Each stock symbol is a link to a stock…
-
FREE BIO-TECH STOCK CATALYST REPORT FOR WEEK OF 02-22-2026 TO 02-28-2026
We’re excited to announce the release of our latest free bio tech stock catalyst report for the upcoming week. This new free stock report highlights bio tech companies that have an upcoming important event to help traders and investors make informed decisions in today’s dynamic environment. Each stock symbol is a link to a stock…
$ALDX, $ALXO, $BBIO, $CGEN, $FULC, $GANX, $IMRX, $TARA, $XNCR, ASCO Genitourinary Cancers Symposium, biopharmaceutical, clinical-research, fda, new drug application, Oppenheimer 36th Annual Healthcare Life Sciences Conference, pr-newswire, press-releases, Wells Fargo Executive Biotech Summit, World ADC London 2026 -
FDA Approves Groundbreaking All-Oral, Fixed-Duration Treatment for Previously Untreated CLL
NYSE: $ABBV A Significant Advance in Chronic Lymphocytic Leukemia Treatment The U.S. Food and Drug Administration (FDA) has granted approval for the combination treatment of VENCLEXTA® (venetoclax) and acalabrutinib for adult patients newly diagnosed with chronic lymphocytic leukemia (CLL). This pivotal decision, supported by robust data from the Phase 3 AMPLIFY trial, introduces the first…
-
10x Genomics Scheduled to Present at 46th Annual TD Cowen Health Care Conference
NASDAQ: $TXG 10x Genomics, Inc., a prominent innovator in the fields of single cell and spatial biology, has confirmed its participation in a significant industry event next month. The company announced that key members of its management team are slated to present at the highly anticipated 46th Annual TD Cowen Health Care Conference. The scheduled…
-
Compugen Set to Present at Key Investor Conferences in Early 2026
NASDAQ: $CGEN Compugen Ltd., a clinical-stage company pioneering cancer immunotherapy through advanced AI/ML-powered computational drug target discovery, has announced its management team will be participating in two significant investor conferences in the coming months. These appearances offer an important opportunity for stakeholders to gain insight into the company’s progress across its differentiated pipeline. The first…
-
QuidelOrtho Announces Presentation at Prestigious Raymond James 47th Annual Institutional Investor Conference
NASDAQ: $QDEL QuidelOrtho Corporation, a recognized global leader in innovative in vitro diagnostics, has officially announced its participation in a significant industry event: the Raymond James 47th Annual Institutional Investor Conference. This presentation offers a valuable opportunity for investors, analysts, and industry stakeholders to gain direct insight into the company’s strategic direction, recent performance, and…
-
NeuroSense’s PrimeC Shows Remarkable 65% Reduction in ALS Mortality Risk and Over 14-Month Survival Extension
NASDAQ: $NRSN NeuroSense Therapeutics Ltd., a biotechnology company concentrating on developing treatments for neurodegenerative conditions, has recently released compelling long-term survival data from its completed PARADIGM Phase 2b clinical trial assessing PrimeC for amyotrophic lateral sclerosis (ALS). This extended analysis confirms a clinically significant and statistically robust improvement in overall survival for patients treated with…
-
FDA Greenlights FILKRI™: Accord BioPharma Completes Comprehensive G-CSF Portfolio for Oncology Support
Accord BioPharma Secures FDA Approval for FILKRI™ (filgrastim-laha), Biosimilar to NEUPOGEN® Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd., has announced a significant milestone: the U.S. Food and Drug Administration (FDA) has approved FILKRI™ (filgrastim-laha). This product is a biosimilar to the established reference product, NEUPOGEN® (filgrastim). The approval, announced on February 17,…
-
Bio-Techne’s Ella Platform Secures CE-IVD Mark, Revolutionizing European Immunoassay Testing
NASDAQ: $TECH Bio-Techne Corporation, a leading global supplier of life science tools, reagents, and diagnostic products, has announced a major milestone: the Ella benchtop immunoassay platform has officially achieved CE-IVD marking and is now available for purchase throughout the European Union. This crucial certification opens the door for European clinical laboratories to adopt Ella’s industry-leading…
-
SOPHiA GENETICS Expands U.S. Footprint with Agreements with Two Major Integrated Health Systems
NASDAQ: $SOPH SOPHiA GENETICS, a recognized leader in AI-driven precision medicine, has significantly augmented its presence in the United States through agreements with two substantial, integrated healthcare systems. This expansion marks a pivotal moment in bringing advanced genomic analysis to a wider patient population across key regions. These two newly integrated institutions represent some of…